Nocturia improved 43% in patients receiving oral desmopressin alone and 64.3% in those receiving desmopressin and an alpha-blocker.
Desmopressin reduced the number of nocturnal voids by 0.85 compared with placebo.
Men with nocturia have a 1.4-fold greater risk of death than men without nocturia, after adjustment for age and major comorbidities.
The antidiuretic effects of desmopressin are mediated by stimulation of vasopressin 2 (V2) receptors, thereby increasing water reabsorption in the kidneys, and reducing urine production.
Lowering nocturnal urine production and enabling patients to void consistently at capacity may ease nocturia in men with low bladder capacity.
For men with nocturnal polyuria, the rate of urine production dropped off as the night progressed.
International Continence Society (ICS) standards offer useful guidance for nocturia management, according to the authors of a new report.
In a study, advanced glycation end products were significantly higher in people with nocturia.
In a study, nighttime voiding significantly correlated with smaller dips in nocturnal blood pressure.
Having 3 or more voids per night was associated with 72% excess death risk.
German study revealed a 13% higher risk of falls among patients with vs without nocturia.
An expert panel developed a framework of 22 nocturia phenotypes that could set the stage for devising diagnostic and treatment pathways and stimulating research.
Nearly 55% of men with lower urinary tract symptoms suffer from nocturnal polyuria, according to a study conducted in Italy.
In a phase 2 trial, treatment with an acetaminophen-ibuprofen combination was associated with a significant reduction in nocturnal voids and improved quality of life compared with placebo.
In a study, 8 mg of silodosin daily for 12 weeks was associated with a significant reduction in nocturia episodes.
A recent paper provides 8 questions to ask patients to elicit information that enables targeted treatment of nocturia.
Small study found that 2 mg of melatonin taken at bedtime did not significantly decrease the mean number of nocturia episodes vs placebo.
Nocdurna carries a Boxed Warning for hyponatremia.
Treatment appeared to reduce fall risk among older adults.
Study confirms associations between nocturia and older age, female sex, overactive bladder, and diabetes.
More than three-quarters of men with nocturnal polyuria had non-dipping blood pressure compared with less than half of men with other causes of nocturia.
Over 12 weeks of treatment, the mean number of nocturia episodes decreased by 1.1 and 0.9 in men who were and were not bothered by their symptoms, a non-significant difference between groups.
Men experiencing 3 or more nocturia episodes per night had a 43% increased mortality risk in adjusted analyses.
Women in service-related occupations were 40% more likely to complain of nocturia than office workers with easy access to bathrooms.
Men with metabolic syndrome or a smoking history had more than triple the risks for persistent moderate to severe nocturia after TURP.
Nocturnal polyuria risk factors such as sleep apnea and pedal edema were underrepresented in the sample population compared with the general population.
A study found that 28.8% of women in a national database reported getting up 2 or more times per night to urinate.
No significant difference in nocturia risk found in patients with higher and lower sodium intake.
Obese individuals and those with central obesity have 1.4- and 1.7-fold greater odds of urinary incontinence (UI), respectively, and 1.4- and 1.9-fold greater odds of urge UI.
In a study, only 5% of nocturia and nocturnal polyuria were prescribed oral desmopressin.
Renal and Urology News Articles
- Gadolinium-Based Contrast May Up Acute Kidney Injury Risk in CKD
- Delayed Prostate Cancer Treatment May Up Relapse Risk
- Review: Desmopressin Decreases Nocturia Episodes
- Surgery, Radiation Regimens for High-Grade PCa Offer Similar Outcomes
- Salvage Prostatectomy May Benefit Some Prostate Cancer Patients
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)